India · Delayed Price · Currency is INR Shaily Engineering Plastics Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw robust growth in healthcare and industrial segments, with healthcare revenue up 139% and overall margins improving significantly. New launches in pen injectors, entry into semiconductors, and strong export performance position the company for continued expansion.
-
Q3 FY 2026 delivered 27% revenue growth and 43% EBITDA growth, led by a surge in healthcare segment revenues and margin expansion. Major capacity expansions are underway, including a new Abu Dhabi facility, with strong contract backing and robust demand for GLP-1 pen injectors.
-
Revenue grew 34% year-over-year in Q2 FY 2026, led by a 163% surge in healthcare segment sales and strong margin expansion. Capacity is being doubled to meet rising demand, with new device launches and global partnerships driving future growth.
-
Q1 FY 2026 saw 38% revenue growth and a 181% surge in healthcare segment revenue, with EBITDA margin expanding to 28.5%. Major capacity expansions are underway, targeting 70–75 million pen capacity by early FY 2027, and 50–60% of this is backed by customer commitments.
Fiscal Year 2025
-
Revenue grew 22% YoY to INR 787 crores in FY 2025, with EBITDA margin up 350 bps to 22.7%. Healthcare segment surged 53% YoY, driven by GLP-1 pen platforms and new contracts. CapEx of INR 150 crores planned for pen expansion, with strong growth and margin improvement expected.
-
Q3 FY 2025 saw 25% revenue growth and 73% PAT growth, led by a 52% surge in healthcare. Six new healthcare contracts and two global retail wins support future growth, with major capacity expansions planned through 2026.
-
Q2 FY25 saw 22% revenue growth and margin expansion, led by a 94% surge in healthcare. Capacity expansions for insulin and semaglutide pens are underway, with healthcare expected to reach 25% of revenues in 2-3 years. Utilization and profitability are set to improve further.
-
Q1 FY 2025 saw 13% revenue growth and margin expansion, driven by strong export performance and new business wins in healthcare, consumer, and industrial segments. Major orders for insulin pens and new device launches are set to boost future growth, with capacity expansion planned.